论文部分内容阅读
目的观察紫杉醇联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法31例晚期非小细胞肺癌患者给予紫杉醇与顺铂联合治疗,紫杉醇135mg/m2第1天静脉滴注3h以上,顺铂30mg/m2第2,3,4天静脉滴注,21d为1个周期,每例患者治疗2周期以上。结果全组无完全缓解病例,部分缓解12例,稳定8例,进展5例,总有效率38.7%。Karnofsky评分增加者占58.1%(18/31)。最常见的毒副反应是骨髓抑制(白细胞减少为54.8%)和消化道反应(恶心、呕吐占64.5%),其余毒性反应轻微,可耐受。结论紫杉醇联合顺铂治疗晚期非小细胞肺癌疗效较好,毒性可以耐受,可作为一线治疗方案。
Objective To observe the short-term curative effect and toxicity of paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 31 patients with advanced non-small cell lung cancer were treated with combination of paclitaxel and cisplatin. Paclitaxel 135mg / m2 was given intravenously for more than 3h on the first day and cisplatin 30mg / m2 on the 2nd, Cycle, each patient treatment more than 2 cycles. Results There was no complete remission in all cases, with partial remission in 12 cases, stable in 8 cases and progression in 5 cases, with a total effective rate of 38.7%. Karnofsky score increased accounted for 58.1% (18/31). The most common adverse reactions were myelosuppression (leukopenia 54.8%) and digestive tract reactions (nausea and vomiting 64.5%) with minimal toxicity and tolerability. Conclusion paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer has good curative effect and toxicity can be tolerated, which can be used as first-line treatment.